|Metabolism||by monoamine oxidase|
|Biological half-life||2–3 hours|
|Excretion||82% urine; 12% faeces|
|Chemical and physical data|
|Molar mass||269.345 g/mol|
|3D model (Jmol)|
|(what is this?)|
Rizatriptan (trade name Maxalt) is a 5-HT1 receptor agonist of the triptan class of drugs developed by Merck & Co. for the treatment of migraine headaches. It is available in strengths of 5 and 10 mg as tablets and orally disintegrating tablets (Maxalt-MLT).
Maxalt obtained approval by the United States Food and Drug Administration (FDA) on June 29, 1998. It is a second-generation triptan.
Rizatriptan is available only by prescription in Australia, Finland, the United States, Canada and New Zealand. Similarly, it is classed as a POM (Prescription Only Medicine) in the United Kingdom, Italy (as Rizaliv), France, Israel (as Rizalt), The Netherlands, Croatia and Spain (as Maxalt).
Ear, nose, and throat:
Mechanism of action
Rizatriptan acts as an agonist at serotonin 5-HT1B and 5-HT1D receptors. Like the other triptans sumatriptan and zolmitriptan, rizatriptan induces vasoconstriction—possibly by inhibiting the release of calcitonin gene-related peptide from sensory neurons in the trigeminal nerve.
- "Rizatriptan". MedlinePlus. U.S. National Library of Medicine.
- Millson, D; Tepper, S (2000). "Migraine pharmacotherapy with oral triptans: a rational approach to clinical management.". Expert Opin Pharmacother. 1 (3): 391–404. doi:10.1517/146565184.108.40.2061. PMID 11249525.
- Wellington, K; Plosker, G. L. (2002). "Rizatriptan: An update of its use in the management of migraine". Drugs. 62 (10): 1539–74. doi:10.2165/00003495-200262100-00007. PMID 12093318.